Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 73 articles:
HTML format
Text format



Single Articles


    October 2017
  1. TAKEUCHI K, Shimoyama T, Yamamoto T
    Comparison of Safety and Efficacy of Tacrolimus versus Infliximab for Active Ulcerative Colitis.
    Dig Dis. 2017 Oct 19. doi: 10.1159/000481815.
    PubMed     Text format     Abstract available


    September 2017
  2. ASL BAAKHTARI S, McCombie A, Ten Bokkel Huinink S, Irving P, et al
    Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids.
    Dig Dis. 2017 Sep 2. doi: 10.1159/000478772.
    PubMed     Text format     Abstract available


    June 2017
  3. CAI JX, Barrow J, Parian A, Brant SR, et al
    Routine Pouchoscopy Prior to Ileostomy Takedown May Not Be Necessary in Patients with Chronic Ulcerative Colitis.
    Dig Dis. 2017 Jun 9. doi: 10.1159/000475808.
    PubMed     Text format     Abstract available


    April 2017
  4. MAHLICH J, Matsuoka K, Sruamsiri R
    Shared Decision Making and Treatment Satisfaction in Japanese Patients with Inflammatory Bowel Disease.
    Dig Dis. 2017 Apr 6. doi: 10.1159/000471795.
    PubMed     Text format     Abstract available


    March 2017
  5. ELIADOU E, Kini G, Huang J, Champion A, et al
    Intravenous Iron Replacement Improves Quality of Life in Hypoferritinemic Inflammatory Bowel Disease Patients with and without Anemia.
    Dig Dis. 2017 Mar 24. doi: 10.1159/000468145.
    PubMed     Text format     Abstract available


    January 2017
  6. PROTIC M, Markovic S, Tarabar D
    Case Report: Acute Flair of Ulcerative Colitis during Pregnancy Is Still a Major Problem.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  7. REINISCH W
    Fecal Microbiota Transplantation in Inflammatory Bowel Disease.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  8. BUER L, Hoivik ML, Medhus AW, Moum B, et al
    Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  9. COSNES J
    What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy?
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  10. DURICOVA D
    What Can We Learn from Epidemiological Studies in Inflammatory Bowel Disease?
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  11. BETTENWORTH D, Rieder F
    Pathogenesis of Intestinal Fibrosis in Inflammatory Bowel Disease and Perspectives for Therapeutic Implication.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  12. DOROFEYEV AE, Rassokhina OA, Dorofeyeva AA
    Late-Onset of Acute Severe Ulcerative Colitis: Clinical Case.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  13. KRUIS W, Nguyen PG, Morgenstern J
    Promises and Dangers of Combination Therapy.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  14. GILS A
    Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable Cost.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  15. HIGGINS PD
    Measurement of Fibrosis in Crohn's Disease Strictures with Imaging and Blood Biomarkers to Inform Clinical Decisions.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  16. STANGE EF
    Improvement of a 'Leaky' Intestinal Barrier.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  17. ROGLER G, Biedermann L, Scharl M
    Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor-alpha Therapy: Pathophysiology and Clinical Implications.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  18. SANDS BE
    Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  19. JAHNSEN J, Kaasen Jorgensen K
    Experience with Biosimilar Infliximab (Remsima(R)) in Norway.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  20. DRASTICH P, Oliverius M
    Crohn's Disease and Intestinal Transplantation.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  21. VEGH Z, Kurti Z, Lakatos PL
    Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  22. FORBES GM
    Mesenchymal Stromal Cell Therapy in Crohn's Disease.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  23. KVERKA M, Tlaskalova-Hogenova H
    Intestinal Microbiota: Facts and Fiction.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  24. HAWKEY CJ
    Hematopoietic Stem Cell Transplantation in Crohn's Disease: State-of-the-Art Treatment.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


  25. KOLAR M, Duricova D, Bortlik M, Hruba V, et al
    Infliximab Biosimilar (Remsima) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Dig Dis. 2017;35.
    PubMed     Text format     Abstract available


    March 2016
  26. LOPETUSO LR, Petito V, Zambrano D, Orlando D, et al
    Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease.
    Dig Dis. 2016;34:202-209.
    PubMed     Text format     Abstract available


  27. SHARARA AI
    When to Start Immunomodulators in Inflammatory Bowel Disease?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  28. KNIGHT SC
    Dendritic Cell-T-Cell Circuitry in Health and Changes in Inflammatory Bowel Disease and Its Treatment.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  29. HANAUER SB
    Oral or Topical 5-ASA in Ulcerative Colitis.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  30. BURMAN S, Hoedt EC, Pottenger S, Mohd-Najman NS, et al
    An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  31. EL-KHIDER F, McDonald C
    Links of Autophagy Dysfunction to Inflammatory Bowel Disease Onset.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  32. ZHOU G, Song Y, Yang W, Guo Y, et al
    ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  33. GUO C, Wu K
    Risk Genes of Inflammatory Bowel Disease in Asia: What Are the Most Important Pathways Affected?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  34. KHANNA R, Mosli MH, Feagan BG
    Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


    January 2016
  35. KANIS SL, van der Woude CJ
    Proper Use of Inflammatory Bowel Disease Drugs during Pregnancy.
    Dig Dis. 2016;34 Suppl 1:61-6.
    PubMed     Text format     Abstract available


  36. ROGLER G, Zeitz J, Biedermann L
    The Search for Causative Environmental Factors in Inflammatory Bowel Disease.
    Dig Dis. 2016;34 Suppl 1:48-55.
    PubMed     Text format     Abstract available


  37. MANTZARIS GJ
    Anti-TNFs: Originators and Biosimilars.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  38. BERNSTEIN CN
    Psychological Stress and Depression: Risk Factors for IBD?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  39. DANESE S, Fiocchi C
    Endothelial Cell-Immune Cell Interaction in IBD.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  40. FEDORAK RN, Ismond KP
    Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  41. LEONG RW, Mitrev N, Ko Y
    Hygiene Hypothesis: Is the Evidence the Same All Over the World?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  42. KRUIS W, Phuong Nguyen G
    Iron Deficiency, Zinc, Magnesium, Vitamin Deficiencies in Crohn's Disease: Substitute or Not?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  43. MAO R, Hu PJ
    The Future of IBD Therapy: Where Are We and Where Should We Go Next?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  44. WRIGHT EK
    Calprotectin or Lactoferrin: Do They Help.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  45. BLUMBERG RS
    Environment and Genes: What Is the Interaction?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  46. YANG SK
    Personalizing IBD Therapy: The Asian Perspective.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  47. CHO JH
    The Promise of Epigenetics. Has It Delivered New Insights?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  48. IACUCCI M, Ghosh S
    Mucosal Healing - How Deep Is Enough?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  49. GEARRY RB
    IBD and Environment: Are There Differences between East and West.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  50. VAVRICKA SR, Rogler G, Biedermann L
    High Altitude Journeys, Flights and Hypoxia: Any Role for Disease Flares in IBD Patients?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  51. KURTI Z, Vegh Z, Golovics PA, Lakatos PL, et al
    'Treat to Target' - Lessons Learnt.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  52. ROGLER G
    Preface.
    Dig Dis. 2016;34.
    PubMed     Text format    


  53. COSNES J
    Smoking and Diet: Impact on Disease Course?
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  54. HERFARTH HH
    Methotrexate for Inflammatory Bowel Diseases - New Developments.
    Dig Dis. 2016;34.
    PubMed     Text format     Abstract available


  55. KUMP P, Hogenauer C
    Any Future for Fecal Microbiota Transplantation as Treatment Strategy for Inflammatory Bowel Diseases?
    Dig Dis. 2016;34 Suppl 1:74-81.
    PubMed     Text format     Abstract available


  56. KHANNA R, Feagan BG
    Emerging Therapies for Inflammatory Bowel Diseases.
    Dig Dis. 2016;34 Suppl 1:67-73.
    PubMed     Text format     Abstract available


  57. LISSNER D, Siegmund B
    Are Immunosuppressants Becoming Obsolete?
    Dig Dis. 2016;34 Suppl 1:56-60.
    PubMed     Text format     Abstract available


  58. HILDNER K, Punkenburg E, Abendroth B, Neurath MF, et al
    Immunopathogenesis of IBD: Batf as a Key Driver of Disease Activity.
    Dig Dis. 2016;34 Suppl 1:40-7.
    PubMed     Text format     Abstract available


  59. ATREYA R, Neurath MF
    Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases.
    Dig Dis. 2016;34:552-7.
    PubMed     Text format     Abstract available


  60. XAVIER RJ
    Microbiota as Therapeutic Targets.
    Dig Dis. 2016;34:558-65.
    PubMed     Text format     Abstract available


    September 2015
  61. KHANNA R, Mosli MH, Feagan BG
    Targeting Leukocyte Trafficking in Inflammatory Bowel Disease: What Is the Clinical Evidence?
    Dig Dis. 2015;33 Suppl 1:95-104.
    PubMed     Text format     Abstract available


  62. DE PRETER V
    Metabolomics in the Clinical Diagnosis of Inflammatory Bowel Disease.
    Dig Dis. 2015;33 Suppl 1:2-10.
    PubMed     Text format     Abstract available


  63. SIEGMUND B
    Management of Mild-to-Moderate Ulcerative Colitis.
    Dig Dis. 2015;33 Suppl 1:90-94.
    PubMed     Text format     Abstract available


  64. FIOCCHI C
    Tailoring Treatment to the Individual Patient - Will Inflammatory Bowel Disease Medicine Be Personalized?
    Dig Dis. 2015;33 Suppl 1:82-89.
    PubMed     Text format     Abstract available


  65. BAERT F
    Is There a Role for Therapeutic Drug Monitoring of Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease.
    Dig Dis. 2015;33 Suppl 1:70-77.
    PubMed     Text format     Abstract available


  66. BERNHEIM O, Axelrad J, Itzkowitz SH, Colombel JF, et al
    Previous Cancer/Lymphoma and Refractory Inflammatory Bowel Disease.
    Dig Dis. 2015;33 Suppl 1:44-49.
    PubMed     Text format     Abstract available


  67. ROGLER G, Vavricka SR, Biedermann L
    Integrating Imaging into Clinical Practice in Inflammatory Bowel Disease.
    Dig Dis. 2015;33 Suppl 1:37-43.
    PubMed     Text format     Abstract available


  68. KUCHARZIK T, Petersen F, Maaser C
    Bowel Ultrasonography in Inflammatory Bowel Disease.
    Dig Dis. 2015;33 Suppl 1:17-25.
    PubMed     Text format     Abstract available


  69. MARAFINI I, Angelucci E, Pallone F, Monteleone G, et al
    The IL-12/23/STAT Axis as a Therapeutic Target in Inflammatory Bowel Disease: Mechanisms and Evidence in Man.
    Dig Dis. 2015;33 Suppl 1:113-119.
    PubMed     Text format     Abstract available


  70. BEJAOUI M, Sokol H, Marteau P
    Targeting the Microbiome in Inflammatory Bowel Disease: Critical Evaluation of Current Concepts and Moving to New Horizons.
    Dig Dis. 2015;33 Suppl 1:105-112.
    PubMed     Text format     Abstract available


    January 2015
  71. HALL B, Holleran G, McNamara D
    Small bowel Crohn's disease: an emerging disease phenotype?
    Dig Dis. 2015;33:42-51.
    PubMed     Text format     Abstract available


  72. DEVKOTA S, Chang EB
    Interactions between Diet, Bile Acid Metabolism, Gut Microbiota, and Inflammatory Bowel Diseases.
    Dig Dis. 2015;33:351-6.
    PubMed     Text format     Abstract available


  73. BONATO G, Cristoferi L, Strazzabosco M, Fabris L, et al
    Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat.
    Dig Dis. 2015;33 Suppl 2:140-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: